LIVE TV
ZEE Business
ZEE BUSINESS
हिंदी में पढ़ें  हिंदी में पढ़ें
Live TV
Live TV
  • Home
  • Budget 2021
  • Personal Finance
    • PPF
    • Mutual Funds
    • Income tax
    • EPFO
    • Income Tax Calculator
    • Personal Loan Calculator
    • Car Loan Calculator
    • Home Loan Calculator
    • SIP calculator
    • SWP Calculator
    • MF Returns Calculator
    • Lumpsum Calculator
  • India
    • Companies
    • Property
    • Startups
    • Uidai
  • Economy
    • Aviation
  • Tech
    • Mobiles
    • Apps
  • Auto
    • Cars
    • Bikes
  • Markets
    • Commodities
    • Currency
  • Jobs
  • Indian Railways
  • World
    • Economy
    • Politics
    • Markets
  • videos
  • photos
  • Authors
  • More ...
    • VIDEOS
    • PHOTOS
Read in App
Business News » Companies News

Sun Pharma, China Medical System Holdings enter into two license agreements

Sun Pharmaceutical Industries Ltd on Thursday announced that one of its wholly-owned subsidiaries has entered into a licensing agreement with a subsidiary of China Medical System Holdings Ltd. 

  • Twitter
  • Facebook
  • Linkedin
  • whatapp
  • View in App
Sun Pharma, China Medical System Holdings enter into two license agreements
Dilip Shanghvi, Managing Director, Sun Pharma, said in a statement: “This licensing agreement marks our entry into the Greater China market which is the second largest pharmaceutical market globally. Image: Reuters
Written By: ZeeBiz WebTeam
Updated: Thu, Jun 27, 2019
06:33 pm
ZeeBiz WebDesk
RELATED NEWS
Now, Sun Pharma, Cipla, Cadila Healthcare, Torrent Pharma, DRL, Eris Life are key stocks to watch Now, Sun Pharma, Cipla, Cadila Healthcare, Torrent Pharma, DRL, Eris Life are key stocks to watch
Sun Pharma Share Price: Specialty business is witnessing improved traction Sun Pharma Share Price: Specialty business is witnessing improved traction
Sun Pharma Share Price Today: All drugs listed - check how they are doing and what is likely to happen Sun Pharma Share Price Today: All drugs listed - check how they are doing and what is likely to happen
Stocks to Buy With Anil Singhvi: Sanjiv Bhasin recommends 3 money-making blue chips Stocks to Buy With Anil Singhvi: Sanjiv Bhasin recommends 3 money-making blue chips
Diwali to Diwali Rocket Shares With Anil Singhvi: Westlife and Sun Pharma to give spectacular returns Diwali to Diwali Rocket Shares With Anil Singhvi: Westlife and Sun Pharma to give spectacular returns

Sun Pharmaceutical Industries Ltd on Thursday announced that one of its wholly-owned subsidiaries has entered into a licensing agreement with a subsidiary of China Medical System Holdings Ltd. (CMS) for the development and commercialization of Tildrakizumab, an innovative biologic product, for psoriasis and psoriatic arthritis in Greater China (including Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region and Taiwan). Sun Pharma's subsidiary has also entered into an exclusive licensing agreement with a subsidiary of China Medical System Holdings Ltd. (CMS) for the development and commercialization of Cyclosporine A 0.09% (CsA) eye drops, which is an innovative formulation, for dry eye disease in Greater China.

In separate statements, Sun Pharma said, "Under terms of the license agreement, CMS will pay Sun Pharma an initial upfront payment, regulatory and sales milestone payments, and royalties on net sales, the terms of which are confidential. CMS will be responsible for development, regulatory filings and commercialization of the product in China."

"The initial tenure of the agreement shall be 15 years from the first commercial sale of Tildrakizumab in Greater China, and may be extended for additional 3 years’ subject to certain conditions defined in the agreement," it added.

Cyclosporine A 0.09% (CsA) eye drops

Cyclosporine A 0.09% ophthalmic solution (CsA) is a patented, novel, proprietary nanomicellar formulation in a clear, preservative-free, aqueous solution. This nanomicellar technology uses micelles, which are gelatinous aggregates of amphipathic (both hydrophobic and hydrophilic) molecules formed at a well-defined concentration.

Tildrakizumab-asmn

Tildrakizumab-asmn is a humanized lgG1/k monoclonal antibody designed to selectively bind to the p19 subunit of interleukin-23 (IL-23) and inhibit its interaction with the IL-23 receptor, leadingto inhibition of the release of pro-inflammatory cytokines and chemokines. It was approved by USFDA in March 2018 and is being currently marketed in the US under the ILUMYATM brand name.

Dilip Shanghvi, Managing Director, Sun Pharma, said in a statement: “This licensing agreement marks our entry into the Greater China market which is the second largest pharmaceutical market globally. Sun Pharma is committed to growing its dermatology franchise, with Tildrakizumab as its lead product. We continue to build our pipeline and capabilities in this important therapeutic area of significant unmet need. We are excited to be partnering with a leading pharmaceutical company like CMS to offer Tildrakizumab as an alternative treatment for psoriasis and psoriatic arthritis in Greater China."

Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.

TAGS:
Sun Pharma
RELATED NEWS
Now, Sun Pharma, Cipla, Cadila Healthcare, Torrent Pharma, DRL, Eris Life are key stocks to watch Now, Sun Pharma, Cipla, Cadila Healthcare, Torrent Pharma, DRL, Eris Life are key stocks to watch
Sun Pharma Share Price: Specialty business is witnessing improved traction Sun Pharma Share Price: Specialty business is witnessing improved traction
Sun Pharma Share Price Today: All drugs listed - check how they are doing and what is likely to happen Sun Pharma Share Price Today: All drugs listed - check how they are doing and what is likely to happen
Stocks to Buy With Anil Singhvi: Sanjiv Bhasin recommends 3 money-making blue chips Stocks to Buy With Anil Singhvi: Sanjiv Bhasin recommends 3 money-making blue chips
Diwali to Diwali Rocket Shares With Anil Singhvi: Westlife and Sun Pharma to give spectacular returns Diwali to Diwali Rocket Shares With Anil Singhvi: Westlife and Sun Pharma to give spectacular returns

LATEST NEWS

Tech analysis on Big Bull Rakesh Jhunjhunwala stocks: Tata Motors, Titan, Lupin and Escorts

Indian Pro Music League: Full list of IMPL teams - God of all music shows is here!

Redmi Note 10 series India launch: Check first look, key specs and other details here

SBI reduces home loan rates to 6.70 pc

Rakesh Jhunjhunwala stock: This Big Bull holding gets a target hike I Details here

Alia Bhatt launches her ''Eternal Sunshine Productions''

Property Buying Tips: 5 things to keep in mind before buying a home in 2021

Modi government creates RECORD! New feat achieved in highways construction - Nitin Gadkari confirms this

REVEALED: 'Laga bhi diya...' - What PM Narendra Modi told nurse P Niveda after COVID-19 vaccine shot

Sovereign Gold Bonds Latest News: Looking for cheaper Gold? Here is your opportunity? Know here how to OPTIMISE gains

  • India News
  • World News
  • Companies News
  • Market News
  • Personal Finance News
  • Technology News
  • Automobile News
  • Small Business News
  • Income Tax Calculator
  • Live TV
  • Videos
  • Photos
  • Author
  • Rss Feed
  • Advertise with us
  • Privacy Policy
  • Legal Disclaimer

Latest Trending Updates

  • EPFO
  • Budget 2020
  • Income Tax Return
  • Auto Expo 2020
  • Home Loan
  • Business News

Trending Topics

  • Income Tax
  • income Tax Calculator
  • 7th Pay Commission
  • Reserve Bank of India
  • GST
  • Latest Business News

Follow us on

zeebiz
zeebiz

Partner Sites

  • Zee News
  • Hindi News
  • Marathi News
  • Bengali News
  • Tamil News
  • Malayalam News
  • Gujarati News
  • Telugu News
  • Kannada News
  • DNA
  • WION
Copyright © Zee Media Corporation Ltd. All rights reserved